MOTS-c

What MOTS-c actually is

MOTS-c (mitochondrial open reading frame 16 short peptide) is a 17-amino-acid fragment translated from a region of the human mitochondrial genome that, until it was characterised, looked to most people like junk sequence. That is the reason it caught the attention of the longevity research community: it is one of the very few peptides with a human gene behind it, not a molecule that was engineered to imitate something else. In 2015, Raha Ahmad and colleagues at the University of Washington (the laboratory of Michael Brown, co-winner of the 1985 Nobel Prize for the discovery of the LDL receptor) showed that the corresponding gene region is transcribed into a protein in human muscle and fat, that the protein is processed, and that the short fragment — MOTS-c — is what gets exported and can act on neighbouring cells. That finding, published in Science, is the anchor of the entire research programme around the compound.

Since then the preclinical literature has built up almost entirely in mouse and cellular models. The consistent themes are: MOTS-c appears to act as a metabolic homeostasis signal — a way for cells that are energy-stressed or metabolically stressed to tell neighbouring cells to adjust — and that injecting it can improve a range of metabolic readouts in older or diet-stressed mice. The most-cited results include improved glucose tolerance and insulin sensitivity in obese and ageing mice, improved running capacity and muscle endurance, and protection of muscle during caloric restriction. A 2019 paper from the same group reported that chronic MOTS-c treatment in mice restored exercise-like benefits including improved mitochondrial function in muscle, and there is evidence it can upregulate mitochondrial biogenesis pathways (the PGC-1α axis) in a way that is mechanistically plausible as an exercise mimetic — a compound that reproduces some of the metabolic effects of exercise without the exercise. The phrase "exercise mimetic" is the reason the compound is famous, but it is also worth being clear about: in the published work, MOTS-c did not replace exercise. It improved metabolic parameters in animals that had little exercise, and the effects were partial, not a full workout in a vial.

Where the evidence sits — and where it stops

As of 2026, MOTS-c has no approved human indication anywhere, and it has not completed a full phase 3 programme in a named disease. It is in the same regulatory position as most research peptides: a preclinical candidate with strong and mechanistically coherent animal data, early human safety signals, and a large community of people using it off-label. For a supplier, that matters for two practical reasons. First, the honest label is research chemical — which is how we supply it. Second, the evidence base is real enough to explain the demand but not deep enough to promise anything: if a vendor is telling you MOTS-c "reverses ageing" or "works like exercise", they are reading the mouse papers as if they were human phase 3 data. The defensible summary is: one of the best-studied mitochondrial-derived peptides in the field, with genuinely interesting human-relevant mechanisms, and a human evidence base that is still being written.

MOTS-c in practice: 10mg vs 40mg

We stock two strengths. The 10mg vial is the low-commitment option for first-time buyers and for anyone who wants to run the compound at the lower end of the range most research users work in; the 40mg vial is the working strength for people who have already decided the compound is worth the cost per cycle. Neither strength carries a dosing recommendation on the label — that is deliberately your call, not ours — but the practical difference is simply how long each vial lasts at the amount you choose to run. Both are supplied the same way: research-grade lyophilised powder, batch documentation and COA available per lot, UK dispatch.